Partial Epilepsy Clinical Trial
Official title:
Improving Lesion Detection in Children With MRI-negative Partial Epilepsy Using Diffusion Tensor Imaging
Focal cortical dysplasia is one of the most common lesions responsible for medically refractory epilepsy in the pediatric population. In patients with medically intractable epilepsy, surgery is the only treatment that will lead to seizure freedom. The outcome of epilepsy surgery is worse in patients when there is no lesion identified on routine structural MRI, also known as MRI-negative partial epilepsy. Diffusion tensor imaging (DTI), a novel MRI technique, can be used to evaluate the integrity of the microstructure of the white matter, even when the white matter appears normal on routine MRI.
The aims of this study are firstly to identify DTI abnormalities in the white matter of children with MRI-negative partial epilepsy and MRI-visible FCD compared to normal controls; and secondly to determine if the location of DTI identified abnormalities correlate with the epileptogenic zone as defined using magnetoencephalography (MEG) dipole clusters. Our hypotheses are firstly DTI can demonstrate the anatomic delineation of white matter abnormalities in MRI-negative partial epilepsy and the alteration in DTI indices are similar in MRI-negative partial epilepsy and MRI-visible FCD, which is the positive control; and secondly the anatomical location of DTI identified abnormalities correlate with the epileptogenic zone as defined by MEG dipole clusters. The long-term goal of this study is to improve detection of subtle lesions in children with MRI-negative partial epilepsy so as to improve the surgical outcome of these patients who undergo epilepsy surgery for seizure control. ;
Observational Model: Cohort, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00982787 -
Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy
|
Phase 2 | |
Completed |
NCT00898560 -
Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
|
Phase 1 | |
Recruiting |
NCT01735032 -
Multimodal Imaging in Pre-surgical Evaluation of Epilepsy
|
N/A | |
Completed |
NCT01090934 -
Localizing the Epileptogenic Zone With High Resolution Electroencephalography
|
N/A | |
Terminated |
NCT00391534 -
EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy
|
Phase 3 | |
Terminated |
NCT01496612 -
Buspirone Therapy for Localized Epilepsy
|
Phase 2 | |
Completed |
NCT00900237 -
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
|
Phase 1 | |
Recruiting |
NCT04903314 -
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
|
Phase 1 | |
Completed |
NCT01373190 -
Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy
|
N/A | |
Recruiting |
NCT03478852 -
Investigating Epilepsy: Screening and Evaluation
|
||
Recruiting |
NCT01273129 -
Surgery as a Treatment for Medically Intractable Epilepsy
|
||
Completed |
NCT00001666 -
Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy
|
N/A | |
Completed |
NCT00001932 -
Serotonin Receptors in Seizure Disorders
|
N/A | |
Completed |
NCT00908349 -
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
|
Phase 3 | |
Completed |
NCT02076698 -
Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy
|
Phase 3 | |
Completed |
NCT00706160 -
Language Mapping in Patients With Epilepsy
|
||
Completed |
NCT01397968 -
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
|
Phase 2 | |
Completed |
NCT01866111 -
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
|
Phase 2 | |
Completed |
NCT00957047 -
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
|
Phase 3 | |
Terminated |
NCT01281956 -
PRX-00023 Therapy in Localization-Related Epilepsy
|
Phase 2 |